Menu

Question 2121

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a lytic epiphyseal lesion in her proximal tibia. Biopsy confirms Giant Cell Tumor (GCT) of bone. Because the tumor is deemed unresectable, medical therapy is initiated. The prescribed medication targets which of the following?

. RANKL
. Osteoprotegerin
. VEGF
. Tyrosine kinase
. PD-1

Correct Answer & Explanation

. RANKL


Explanation

Denosumab is a monoclonal antibody that targets RANKL, which is overexpressed by the neoplastic mononuclear stromal cells in GCT of bone. This prevents RANK activation on osteoclasts, dramatically reducing bone resorption and tumor progression.

Question 2122

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with a large, lytic, expansile lesion in the proximal tibia extending to the subchondral bone. Biopsy demonstrates mononuclear cells interspersed with osteoclast-like multinucleated cells. Which targeted pharmacological agent can be used to downstage this tumor prior to surgery?

. Imatinib
. Bisphosphonates
. Rituximab
. Denosumab
. Methotrexate

Correct Answer & Explanation

. Denosumab


Explanation

The diagnosis is Giant Cell Tumor (GCT) of bone. Denosumab, a monoclonal antibody against RANKL, inhibits the recruitment and action of the osteoclast-like giant cells, causing tumor calcification and facilitating surgical curettage.

Question 2123

Topic: Biology, Genetics & Bone Healing

A 4-year-old girl is diagnosed with ANA-positive oligoarticular Juvenile Idiopathic Arthritis (JIA). What is the most critical routine screening required for this patient?

. Slit-lamp examination every 3-4 months
. Echocardiogram yearly
. Pulmonary function tests every 6 months
. Renal ultrasound yearly
. DEXA scan at diagnosis and every 2 years

Correct Answer & Explanation

. Slit-lamp examination every 3-4 months


Explanation

ANA-positive oligoarticular JIA carries the highest risk for asymptomatic uveitis/iridocyclitis. Routine slit-lamp examination every 3-4 months is critical to prevent permanent visual impairment or blindness.

Question 2124

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with an expansive, purely lytic lesion in the distal radius extending to the subchondral bone. Biopsy confirms a Giant Cell Tumor (GCT). For an unresectable or recurrent GCT, which targeted medical therapy is most appropriate?

. Imatinib
. Denosumab
. Zoledronic acid
. Methotrexate
. Rituximab

Correct Answer & Explanation

. Denosumab


Explanation

Denosumab is a monoclonal antibody against RANKL. It prevents the RANK-RANKL interaction, inhibiting the osteoclast-like giant cells driving bone destruction in GCT, leading to tumor regression and ossification.

Question 2125

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with knee pain. Radiographs reveal an eccentric, purely lytic, epiphyseal lesion extending to the subchondral bone of the proximal tibia. Biopsy confirms multinucleated giant cells in a background of mononuclear stromal cells. Which targeted therapy acts as a RANKL inhibitor and is indicated for advanced or unresectable forms of this tumor?

. Imatinib
. Denosumab
. Zoledronic acid
. Doxorubicin
. Methotrexate

Correct Answer & Explanation

. Denosumab


Explanation

Giant cell tumor of bone (GCT) is driven by the overexpression of RANKL by the neoplastic mononuclear stromal cells, which recruits osteoclast-like giant cells. Denosumab, a monoclonal antibody against RANKL, is an effective targeted therapy for advanced or unresectable GCT.

Question 2126

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with knee pain. Radiographs reveal an eccentric, expansile lytic lesion in the distal femoral epiphysis extending to the articular surface. Biopsy shows multinucleated giant cells in a stroma of mononuclear cells. Which of the following is the most appropriate targeted medical therapy?

. Imatinib
. Denosumab
. Bisphosphonates
. Methotrexate
. Doxorubicin

Correct Answer & Explanation

. Denosumab


Explanation

This is a giant cell tumor of bone. Denosumab, a monoclonal antibody against RANKL, is an effective targeted medical therapy that inhibits the osteoclast-like giant cells.

Question 2127

Topic: Biology, Genetics & Bone Healing

A 65-year-old man presents with severe back pain and fatigue. Radiographs show multiple "punched-out" lytic lesions in his skull and vertebral bodies. Laboratory studies reveal hypercalcemia, anemia, and an M-spike on serum protein electrophoresis. The osteolytic lesions in this disease are primarily mediated by the upregulation of which factor?

. OPG (Osteoprotegerin)
. PTH (Parathyroid hormone)
. RANKL
. FGF-23
. BMP-2

Correct Answer & Explanation

. RANKL


Explanation

Multiple myeloma cells secrete various factors, particularly activating RANKL and inhibiting OPG. This leads to massive osteoclast activation and the classic "punched-out" lytic lesions without reactive bone formation.

Question 2128

Topic: Biology, Genetics & Bone Healing

A 4-year-old girl with ANA-positive oligoarticular Juvenile Idiopathic Arthritis (JIA) presents for routine follow-up. Which of the following represents the most critical routine screening recommendation for this patient?

. Slit-lamp examination every 3-4 months
. Annual echocardiogram
. Baseline DEXA scan
. HLA-B27 testing
. Routine pulmonary function tests

Correct Answer & Explanation

. Slit-lamp examination every 3-4 months


Explanation

Young females with ANA-positive oligoarticular JIA are at the highest risk for asymptomatic anterior uveitis. They require frequent slit-lamp examinations every 3-4 months to prevent synechiae and blindness.

Question 2129

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with a lytic lesion in the distal femur extending to the subchondral bone. Biopsy confirms a Giant Cell Tumor. Prior to extended intralesional curettage, the surgeon administers denosumab. What is the mechanism of action of denosumab?

. Inhibits RANKL to prevent osteoclast-like giant cell formation
. Directly induces apoptosis of neoplastic stromal cells
. Inhibits VEGF to reduce tumor angiogenesis
. Binds to RANK receptor on osteoblasts to stimulate new bone
. Cross-links DNA preventing cell replication

Correct Answer & Explanation

. Inhibits RANKL to prevent osteoclast-like giant cell formation


Explanation

Denosumab is a monoclonal antibody that binds to RANKL, preventing its interaction with the RANK receptor. This inhibits the recruitment and maturation of the osteoclast-like giant cells, leading to tumor ossification and easier surgical curettage.

Question 2130

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a large, lytic, epiphyseal-metaphyseal lesion of her distal radius. Biopsy confirms a Giant Cell Tumor of bone (GCTB). She is started on Denosumab prior to surgical intervention. What is the mechanism of action of this medication?

. Direct inhibition of osteoclast proton pumps
. Monoclonal antibody against RANK Ligand (RANKL)
. Selective estrogen receptor modulation
. Tyrosine kinase inhibition of VEGF
. Monoclonal antibody targeting CD20

Correct Answer & Explanation

. Monoclonal antibody against RANK Ligand (RANKL)


Explanation

Denosumab is a human monoclonal antibody that binds to RANKL, preventing it from activating RANK on the surface of osteoclasts. This inhibits the massive osteoclast-like giant cells characteristic of GCTB.

Question 2131

Topic: Biology, Genetics & Bone Healing

A 4-year-old girl is evaluated for recurrent long bone fractures after minimal trauma, blue sclerae, and early hearing loss. Which of the following best describes the underlying biochemical defect?

. Defective osteoclastic bone resorption
. Qualitative or quantitative defect in Type I collagen
. Defective synthesis of Type II collagen
. Inability to synthesize heparan sulfate
. Gain of function in osteoblast Wnt signaling

Correct Answer & Explanation

. Qualitative or quantitative defect in Type I collagen


Explanation

Osteogenesis imperfecta (OI) is primarily caused by mutations in the COL1A1 or COL1A2 genes, leading to defective quantity or quality of Type I collagen. Type I collagen is the major structural protein in bone, sclera, and dentin. Management includes bisphosphonates to increase bone density and surgical rodding for deformity correction.

Question 2132

Topic: Biology, Genetics & Bone Healing

A 25-year-old male presents for a routine orthopedic evaluation following a minor injury. On examination, he is noted to have a highly unusual ability to appose his shoulders anteriorly in the midline. He also has delayed secondary tooth eruption. A mutation in which gene is most likely responsible?

. GNAS1
. RUNX2 (CBFA1)
. EXT1
. COL2A1
. SOX9

Correct Answer & Explanation

. RUNX2 (CBFA1)


Explanation

Cleidocranial dysplasia is an autosomal dominant condition caused by a mutation in the RUNX2 (also known as CBFA1) gene, which is a master transcription factor for osteoblast differentiation. It is characterized by absent or hypoplastic clavicles, delayed closure of cranial sutures, and dental abnormalities. Intramembranous ossification is primarily affected.

Question 2133

Topic: Biology, Genetics & Bone Healing

A 7-year-old boy presents with bilateral hip pain, a waddling gait, and short stature. Radiographs demonstrate delayed ossification of the capital femoral epiphyses and a double-layer patella on the lateral knee view. A mutation in which of the following is most likely responsible?

. Type I collagen
. Type II collagen
. Type X collagen
. Cartilage oligomeric matrix protein (COMP)
. Fibroblast growth factor receptor 3 (FGFR3)

Correct Answer & Explanation

. Cartilage oligomeric matrix protein (COMP)


Explanation

Multiple Epiphyseal Dysplasia (MED) is primarily caused by mutations in the COMP gene or Type IX collagen genes. A double-layer patella is a classic pathognomonic radiographic sign for this condition.

Question 2134

Topic: Biology, Genetics & Bone Healing

A newborn presents with micromelic short stature, severe clubfeet, hitchhiker thumbs, and cystic swelling of the external ears. Which of the following genes is mutated in this condition?

. SLC26A2 (DTDST)
. COL1A1
. RUNX2
. GNAS1
. EXT1

Correct Answer & Explanation

. SLC26A2 (DTDST)


Explanation

Diastrophic dysplasia is an autosomal recessive condition caused by a mutation in the SLC26A2 gene, which encodes a sulfate transporter. It presents with classic hitchhiker thumbs, severe rigid clubfeet, and cauliflower ear deformities.

Question 2135

Topic: Biology, Genetics & Bone Healing

An 8-year-old girl with a history of multiple fractures, blue sclerae, and hearing loss is started on pamidronate therapy. What is the primary mechanism of action of this medication in her condition?

. Inhibits osteoblast apoptosis
. Stimulates type I collagen synthesis
. Inhibits osteoclast-mediated bone resorption
. Promotes chondrocyte proliferation
. Increases renal calcium reabsorption

Correct Answer & Explanation

. Inhibits osteoclast-mediated bone resorption


Explanation

Osteogenesis imperfecta is commonly treated with bisphosphonates (like pamidronate), which inhibit osteoclast-mediated bone resorption. This increases bone density and decreases the fracture rate, though it does not correct the underlying Type I collagen defect.

Question 2136

Topic: Biology, Genetics & Bone Healing

A 6-year-old child presents with a history of multiple low-energy fractures, progressive vision loss, and pancytopenia. Radiographs show diffusely dense bones with a 'bone-within-a-bone' appearance and Erlenmeyer flask deformity of the femurs. The underlying defect primarily involves impaired function of which cell type?

. Osteoblasts
. Osteoclasts
. Chondrocytes
. Fibroblasts
. Hematopoietic stem cells

Correct Answer & Explanation

. Osteoclasts


Explanation

Osteopetrosis is caused by defective osteoclast function (e.g., carbonic anhydrase II or TCIRG1 mutations), leading to an inability to resorb bone. This results in densely sclerotic but brittle bones, marrow obliteration, and cranial nerve entrapment.

Question 2137

Topic: Biology, Genetics & Bone Healing

A 40-year-old male undergoes marginal excision of a nodular, plaque-like cutaneous mass on the trunk. Pathology returns as dermatofibrosarcoma protuberans (DFSP), demonstrating a t(17;22) translocation. Which targeted therapy is FDA-approved for unresectable or metastatic DFSP?

. Doxorubicin
. Imatinib mesylate
. Denosumab
. Pazopanib
. Methotrexate

Correct Answer & Explanation

. Imatinib mesylate


Explanation

DFSP is driven by a t(17;22) translocation that produces a COL1A1-PDGFB fusion protein, leading to constant PDGFR activation. Imatinib mesylate, a tyrosine kinase inhibitor, effectively targets this pathway and is used for unresectable cases.

Question 2138

Topic: Biology, Genetics & Bone Healing

A 5-year-old child with blue sclerae, dentinogenesis imperfecta, and multiple prior fractures is started on intravenous pamidronate for osteogenesis imperfecta. What is the primary mechanism of action of this medication in this patient?

. Stimulates osteoblast-mediated bone formation
. Inhibits osteoclast-mediated bone resorption
. Corrects the underlying COL1A1 mutation
. Increases intestinal calcium absorption
. Promotes renal calcium and phosphate retention

Correct Answer & Explanation

. Inhibits osteoclast-mediated bone resorption


Explanation

Pamidronate is a bisphosphonate that binds to hydroxyapatite and inhibits osteoclast-mediated bone resorption by inducing osteoclast apoptosis. In Osteogenesis Imperfecta, it increases bone mineral density and decreases fracture frequency.

Question 2139

Topic: Biology, Genetics & Bone Healing

A 10-year-old patient presents with a prominent forehead, hypertelorism, and the ability to touch their shoulders together anteriorly. Radiographs reveal delayed cranial suture closure and aplastic clavicles. A mutation in which gene is the primary cause of this condition?

. RUNX2 (CBFA1)
. SOX9
. FGFR3
. COL1A1
. COMP

Correct Answer & Explanation

. RUNX2 (CBFA1)


Explanation

Cleidocranial dysplasia is an autosomal dominant disorder caused by a mutation in RUNX2 (CBFA1), a master transcription factor essential for osteoblast differentiation. It classically presents with hypoplastic clavicles, delayed fontanelle closure, and supernumerary teeth.

Question 2140

Topic: Biology, Genetics & Bone Healing

In secondary fracture healing, chondrocytes play a vital role. What is their primary contribution to the callus formation process?

. Directly forming new lamellar bone
. Secreting osteoinductive growth factors
. Producing a cartilaginous matrix that subsequently undergoes endochondral ossification
. Resorbing necrotic bone fragments
. Differentiating into fibroblasts to form fibrous tissue

Correct Answer & Explanation

. Producing a cartilaginous matrix that subsequently undergoes endochondral ossification


Explanation

Chondrocytes are central to endochondral ossification, the predominant mechanism in secondary fracture healing. They proliferate and lay down a cartilaginous matrix (soft callus), which then hypertrophies, calcifies, and is ultimately replaced by woven bone through a process similar to epiphyseal growth plate development. They do not directly form lamellar bone or primarily secrete osteoinductive growth factors (though they respond to them). Osteoclasts resorb bone, and fibroblasts form fibrous tissue, not chondrocytes.